Form 4: CareDx Director Fred E. Cohen Receives RSU Grant

Director Fred E. Cohen was granted 9,795 restricted stock units as part of his compensation package at CareDx, Inc.

Summary

• Director Fred E. Cohen acquired 9,795 restricted stock units (RSUs) on June 12, 2026.
• The RSUs were granted at a price of $0 per share.
• Following this transaction, the reporting person's total beneficial ownership is 165,060 shares of common stock.
• The RSUs vest 100% on the earlier of the one-year anniversary of the grant or the day before the first Annual Meeting following the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• The grant aligns the director's interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to the reporting person's continuous service to the company.

Future Outlook

The RSUs are scheduled to vest on the earlier of the one-year anniversary of the grant or the day before the first Annual Meeting occurring after the grant date.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure alignment between leadership and shareholders.

Comparison to Industry Standards

• The use of RSU grants for director compensation is consistent with standard practices for mid-cap biotechnology companies.
• The vesting schedule is typical for annual director equity awards.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 9,795 RSUs on the earlier of the one-year anniversary or the day before the next Annual Meeting.

Key Dates

Keywords

CareDx, CDNA, Form 4, Director Compensation, Restricted Stock Units, Insider Transaction